Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma

Nuclear Medicine Communications

Volumn 33, Issue 6, 2012, Pages 591-596

  Manohar, Kuruva ^a   Mittal, Bhagwant Rai ^a   Senthil, Raja ^a   Kashyap, Raghava ^a   Bhattacharya, Anish ^a   Singh, Gurpreet ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

breast cancer; fluorine 18 fluorodeoxyglucose; positron emission tomography computed tomography; recurrence; restaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84860838685     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283516716     Document Type: Article

References (27)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Longterm results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92:1143-1150.
3. Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21:299-310.
4. Probstfeld MR, O'Connell TX. Treatment of locally recurrent breast carcinoma. Arch Surg 1989; 124:1127-1129.
5. Avril N, Rose' CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
6. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18:473-478. (Pubitemid 46359625)
7. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006; 93:707-712. (Pubitemid 43886022)
8. Goerres GW, Michel SC, Fehr MK, Kaim AH, Steinert HC, Seifert B, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13:1635-1644. (Pubitemid 36869357)
9. Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001; 25:829-834. (Pubitemid 32666379)
10. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129:147-153. (Pubitemid 36583695)
11. Lin WY, Tsai SC, Cheng KY, Yen RF, Kao CH. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer: Taiwanese experiences. Cancer Invest 2002; 20:725-729.
12. Lonneux M, Borbath I, Berliere M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 2000; 2:s45-s49.
13. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545-2551. (Pubitemid 44845606)
14. Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging. Hell J Nucl Med 2011; 14:135-139.
15. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33:254-262.
16. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005; 7:369-376. (Pubitemid 44193414)
17. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2. 2011. Available at: http://www.nccn.org/professionals/physician- gls/f-guidelines.asp. [Accessed 17 September 2011].
18. Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int 2011; 108:71-79.
19. Eubank WB. Diagnosis of recurrent and metastatic disease using F-18 fluorodeoxyglucose-positron emission tomography in breast cancer. Radiol Clin North Am 2007; 45:659-667. (Pubitemid 47238390)
20. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001; 42:1334-1337. (Pubitemid 32852607)
21. Eubank WB, Mankoff DA, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of [F-18]-fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004; 183:479-486. (Pubitemid 38970344)
22. Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31:932-939. (Pubitemid 38915646)
23. Evangelista A, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, et al. Tumor markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 2011; 38:293-301.
24. Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011; 22:307-314.
25. 18F-FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375-3379. (Pubitemid 28481635)
26. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010; 28:3154-3159.
27. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005; 46:1144-1150. (Pubitemid 43741076)